# A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

> **NCT00891735** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 1097 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00891735
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-08
- **Final completion:** 2012-08
- **Target enrollment:** 1097 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891735, "A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00891735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*